Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance

Take a look inside the London 2014 Congress


Then register to join us
in Barcelona!

Anterior chamber migration of a dexamethasone implant in a pseudophakic patient without posterior capsular integrity and previous vitrectomy

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Special Cases II

Session Date/Time: Monday 07/09/2015 | 17:00-18:30

Paper Time: 18:04

Venue: Room 11

First Author: : D.D'Eliseo ITALY

Co Author(s): :    A. Bratu   P. Rossini                 

Abstract Details


We report two cases of anterior chamber migration of a dexamethasone implant (Ozurdex(®)) in a pseudophakic patient with an iris-fixated posterior chamber intraocular lens(iris-fixated PCIOL) and a pseudophakic patient with angle-supported lens implantation post vitrectomy, the complication and the management strategies.


Santa Maria delle Croci Hospital, Ravenna, Italy


The medical records of 2 patients with spontaneous migration of a dexamethazone implant were retrospectively reviewed.


the first patient with an iris-fixated PCIOL had prior pars plana vitrectomy for trauma and the second patient with angle-supported lens implantation had previous anterior vitrectomy for complicated cataract. The interval from DEX implant injection to detection of the implant migration into the anterior chamber was 7 days in the first patient and 30 days in the second. The first patient has developed elevated intraocular pressure without corneal decompensation and the second patient has developed corneal decompensation and transitory elevated intraocular pressure. Aspiration was necessary to remove the implant in both patients.


Patients without posterior capsular integrity present a high risk of anterior chamber migration of the Ozurdex(®) implant with possible irreversible complication. The migration is more fast in patient with previous pars plana vitrectomy. In such cases, anti-VEGF therapies should be discussed as an alternative.

Financial Interest:


Back to previous